Advertisement
Screener

IMMUNITYBIO, INC. (IBRX) Payments to Acquire Investments

2.4 / 5 stars · 47/97 Roast Me

IMMUNITYBIO, INC. Payments to Acquire Investments

IMMUNITYBIO, INC. (IBRX) reported Payments to Acquire Investments of $3.00 thousand for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-06.

Discontinued › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireInvestments · last filed 2019-08-06

  • IMMUNITYBIO, INC. payments to acquire investments for the quarter ending 2018-12-31 was $0.00.
  • IMMUNITYBIO, INC. payments to acquire investments for the quarter ending 2018-09-30 was $0.00.
  • IMMUNITYBIO, INC. payments to acquire investments for the quarter ending 2017-12-31 was $0.00.
  • IMMUNITYBIO, INC. payments to acquire investments for the quarter ending 2017-09-30 was $0.00.
  • IMMUNITYBIO, INC. payments to acquire investments for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
  • IMMUNITYBIO, INC. payments to acquire investments for fiscal 2017 was $8.50M.
  • IMMUNITYBIO, INC. payments to acquire investments for fiscal 2016 was $0.00.
Period endPayments to Acquire Investments 3 monthPayments to Acquire Investments 6 monthPayments to Acquire Investments 9 monthPayments to Acquire Investments 12 month
2019-06-30$3.00K
10-Q · filed 2019-08-06
2018-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13
$0.00
derived: sum of 2 quarters · filed 2019-03-13
$0.00
10-K · filed 2019-03-13
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$0.00
10-Q · filed 2018-11-07
2018-06-30$0.00
10-Q · filed 2019-08-06
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13
$0.00
derived: sum of 2 quarters · filed 2019-03-13
$0.00
derived: sum of 3 quarters · filed 2019-03-13
$8.50M
10-K · filed 2019-03-13
2017-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$0.00
derived: sum of 2 quarters · filed 2018-11-07
$8.50M
10-Q · filed 2018-11-07
$8.50M
derived: sum of 4 quarters · filed 2019-03-13
2017-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06
$8.50M
10-Q · filed 2018-08-06
$8.50M
derived: sum of 3 quarters · filed 2019-03-13
$8.50M
derived: sum of 4 quarters · filed 2019-03-13
2017-03-31$8.50M
10-Q · filed 2017-05-08
$8.50M
derived: sum of 2 quarters · filed 2019-03-13
$8.50M
derived: sum of 3 quarters · filed 2019-03-13
$8.50M
derived: sum of 4 quarters · filed 2019-03-13
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13
$0.00
derived: sum of 2 quarters · filed 2019-03-13
$0.00
derived: sum of 3 quarters · filed 2019-03-13
$0.00
10-K · filed 2019-03-13
2016-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
$0.00
derived: sum of 2 quarters · filed 2017-11-07
$0.00
10-Q · filed 2017-11-07
2016-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07
$0.00
10-Q · filed 2017-08-07
2016-03-31$0.00
10-Q · filed 2017-05-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
Immunovant, Inc. (IMVT)United States$7.028B-14.78
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CRISPR Therapeutics AG (CRSP)$5.390B-11.68